Skip to main content
. 2016 Sep;13(3):373–383. doi: 10.20892/j.issn.2095-3941.2016.0028

1.

Summary of the details of RTOG 0630 and PMH-IMRT trial 9,10

Item RTOG 0630 PMH-IMRT-LE-STS
Reproduced with permission from Ref 11. Copyright ASCO 2015 Educational Book
Technique 3D or IMRT IMRT alone
Anatomic site Upper or lower extremity Lower extremity
Chemotherapy Cohort A: (closed Jan 2010)-induction chemotherapy (50 Gy)-concurrent chemotherapy (44 Gy) No chemotherapy
Image guidance 2D or 3D daily image guidance 3D daily online cone-beam CT
Post-op boost (+margins) External beam radiotherapy or brachytherapy (LDR, HDR, or IORT) No postoperative boost
Primary end-point Reduction of late morbidity at 2 years by RTOG/EORTC criteria (> grade 2 lymphedema, subcutaneous fibrosis, joint stiffness) Reduction of wound complications by the SR2 criteria at 120 days
Secondary end-points Similar between both studies Similar between both studies
Target definitions CTV high grade: 3 cm longitudinally; 1.5 cm axially CTV 4 cm longitudinally: 1.5 cm axially. “Flap” is contoured as a region of interest.